[노벨티노빌리티 IPO 리부트]⑤ 박찬희 "시장 수요로 R&D 재정렬"

Novelty Mobility's market-driven R&D realignment signals a strategic pivot from traditional B/T cell-focused antibody development toward differentiated mast cell targeting, establishing a competitive moat in immunoinflammatory and oncology spaces. The integration of AI-powered platforms with novel ADC (antibody-drug conjugate) technologies strengthens the company's clinical pipeline and reflects industry-wide momentum toward precision-targeted therapeutics and data-driven drug discovery.